Activism, advocacy &
global health:
a personal
perspective

Simon Collins
i-Base.info
Outline

- Recap lecture by Jane Bruton.
- HIV Q&A: transmission, testing and treatment?
- HIV positive activist and non scientist.
- i-Base: UK, European, US, SA: treatment literacy and global access.
- HIV in the UK in 2014.
- Links for reading and future issues.
Recap

• US activism: Denver Principles, ACT-UP, TAG and global access.
• Treatment: AZT 1987, ART 1997, update
Survive a Plague and Fire in the Blood.
Denver principles, 1983

Denver principles, 1983

• We condemn attempts to label us as "victims".
• Be involved at every level of decision-making.
• Be included in all AIDS forums with equal credibility.
• Ethics: to inform and protect others
• Right to full explanations of all medical procedures and risks.
• To die–and to LIVE–in dignity.

KNOWLEDGE = POWER!
SILENCE = DEATH!
ACTION = LIFE!
ACT-UP! Fight Back! Fight AIDS!
1998
IAS conference 1998:
“Bridging the Gap”

“Conference halls were haemorrhaging delegates…” – Richard Horton
http://www.tac.org.za
ALL THESE VEGETABLES PREVENT THE ROLLOUT OF ANTIRETROVIRALS — TRUE OR FALSE?

AFRICAN POTATO

BEETROOT

LEMON

GARLIC

MANTO

FALSE: LEMON IS NOT A VEGETABLE.
Generics

The Effects of Generic Competition

Sample of ARV triple-combination: stavudine (d4T) + lamivudine (3TC) + nevirapine (NVP). Lowest world prices per patient per year.

Generic competition has shown to be the most effective means of lowering drug prices. During the last three years, originator companies have often responded to generic competition.
WHO 3x5
HCV, sofosbuvir & DAAs
Generic DAAs


---

<table>
<thead>
<tr>
<th>HCV DAA</th>
<th>Patent expiry</th>
<th>Class/daily dose</th>
<th>Total dose (12 wk)</th>
<th>Predicted cost (US $)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ribavirin</td>
<td>generic</td>
<td>NRTI/1200 mg</td>
<td>84g</td>
<td>$20-63</td>
</tr>
<tr>
<td>daclatasvir</td>
<td>2027</td>
<td>NS5a/60 mg</td>
<td>5g</td>
<td>$10-30</td>
</tr>
<tr>
<td>sofosbuvir</td>
<td>2029</td>
<td>NtRTI/400 mg</td>
<td>34g</td>
<td>$68-136</td>
</tr>
<tr>
<td>faldaprevir</td>
<td>2029</td>
<td>PI/120 mg</td>
<td>10g</td>
<td>$100-210</td>
</tr>
<tr>
<td>simeprevir</td>
<td>2026</td>
<td>PI/150 mg</td>
<td>13g</td>
<td>$130-270</td>
</tr>
</tbody>
</table>
TAG/i-Base pipeline reports

- Better drugs: more effective, easier to tolerate, less resistance
- Cost & access, paediatrics
- HCV and TB coinfections
- Cure research
- PipelineReport.org
UK-CAB (2002)

- Network of UK activists.
- Community Advisory Board ~ 700 members/120 organisations
- BHIVA guidelines and conferences
- Four meetings/year + online forum
- Language: HIV positive (not infected)
- www.ukcab.net
HIV in the UK: 2014

• Public Health England
• 6250 diagnosis in 2013
• 3250 in MSM
• ~3000 heterosexual
• 16% MSM younger than 24 yo
• 10% MSM older than 50 yo

Public Health England:
World AIDS Day 2014

- Hunter Charlton
- Diagnosed in 2012
- age 20
- Gap year in Australia
- One exposure

The Independent (1 December 2014)
Young people and HIV

• “I mean I just always use a condom really... but of course you’ve been in a situation where you haven’t, I mean, everyone has.”

56 Dean Street Clinic

“Young people’s attitudes towards sex & HIV” (12 mins video)

https://www.youtube.com/watch?v=ThCO_8CcHmU
Issues in 2015

- Funding and scale-up.
- Threat to Indian generics.
- Paediatric and maternal care.
- 2\textsuperscript{nd} and 3\textsuperscript{rd}-line treatment.
- TB coinfection: new drugs.
- Hepatitis C: new drugs and pricing.
- When to start, TasP and PrEP.
- HIV cure research.
Further watching

• And the Band Played On (also Jaffe talk with clips: http://www.hivdrugtherapy.org)
• Angels in America
• Blue (Derek Jarman)
• Fire in the Blood (Global access)
• How to survive a plague (ACT-UP/TAG)
• Philadelphia
• Precious
• United in Anger (ACT-UP)
Thank you